摘要 |
<p>The use of an estrogen agonist for the manufacture of a medicament for the treatment or prevention of osteoporosis, cardiovascular disease or breast cancer in a human patient under treatment with warfarin or propranolol without interfering with the action of said warfarin or propranolol.</p> |